rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Adagene Inc. - ADS, each representing 1.25

ADAG · Nasdaq

Health CareBiotechnologyNot moving yet

ADAG stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 7 weeks. It is 43.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 7
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$325K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
35 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$178KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Man Kin TamChief Financial Officerbought2,000at $3.0023 Sep 2026filed 25 Sep 2026
Peter LuoChief Executive Officerbought20,290at $3.1516 Sep 2026filed 17 Sep 2026
Cuong V. DoDirectorbought2,000at $3.7514 Aug 2026filed 18 Aug 2026
Peter LuoChief Executive Officerbought279at $3.655 Aug 2026filed 6 Aug 2026
Peter LuoChief Executive Officerbought22,966at $3.654 Aug 2026filed 6 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders35+11 on the quarter
New · exited17 · 6
Reported value$80.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20266,666,666$28.1M+6,666,666
DEERFIELD MANAGEMENT COMPANY, L.P.new · filed 14 Aug 20262,666,666$11.2M+2,666,666
Siren, L.L.C.new · filed 13 Aug 20262,666,666$11.2M+2,666,666
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 20261,716,711$7.2M+1,108,808+182.4%
HSG Holding Ltdunchanged · filed 13 Aug 20261,343,364$5.6M00.0%
Squadron Capital Management LLCnew · filed 14 Aug 20261,250,000$5.3M+1,250,000
Dauntless Investment Group, LLCadded · filed 13 Aug 2026537,230$2.3M+502,455+1444.9%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026506,934$2.1M+506,934
Exome Asset Management LLCreduced · filed 14 Aug 2026488,293$2.1M-248,552−33.7%
Birchview Capital, LPnew · filed 14 Aug 2026240,000$1.0M+240,000
31 Mar 2023 – 30 Jun 2026
92234Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Man Kin Tam Company insiderChief Financial Officer · last 23 Sep 20261 · 0
Peter Luo Company insiderChief Executive Officer · last 16 Sep 20263 · 0
Cuong Do V Company insiderDirector · last 14 Aug 20261 · 0
Andy Yiu Leung Cheung Company insiderDirector · last 13 Aug 20260 · 0
Li Zhu Company insiderDirector · last 13 Aug 20260 · 0
Ulf Grawunder Company insiderDirector · last 13 Aug 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-279%
Free cash flow marginFY 2025 · to 31 Dec 2025-204%
Return on capital employedFY 2025 · to 31 Dec 2025-40.4%
Debt to equityFY 2025 · to 31 Dec 20250.05×
Research spendFY 2025 · to 31 Dec 2025287%
Revenue growthFY 2024 · to 31 Dec 2024-99.4%
Share count trendFY 2025 · to 31 Dec 20250.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$74.5M
Free cash flowFY 2025 · to 31 Dec 2025−$15.7M

Analyst forecasts

No analyst forecasts yet.